sp should be 5x imho, page-515

Spot on@Beno77.

I would also question the motives of those who advocate selling NOW when we are so close to receiving an important announcement. I am not surprised that some follow advise on HC like gospel.

The irony is HC followers of TA gurus with past credibility will help achieve this self-fulfilling prophecy. Once they know that you are selling your shares following their advise, they will be happy to take them off you . One thing to remember is not all traders win.

PTX story is unfolding and hard to put a value on it. PTX's OmniCAR immune receptor technology platform offers a number of potential benefits over existing CAR-T therapies, including control, safety, flexibility, and efficacy.

PTX CEO had mentioned Xyphos Biosciences sale to Astellas for USD665m. When this transaction happened, Xyphos’ first convertible CAR cell product candidate was in preclinical development and is scheduled to be tested in a first-in-human clinical study in the current year.

https://www.genengnews.com/news/astellas-acquires-xyphos-for-up-to-665m-boosting-cancer-immunotherapy-pipeline/

Even at a SP of 50cents, PTX MC is about AUD320m and feels that this is medium-term potential.

I feel it will be worth the wait.